Revelation Biosciences (NASDAQ:REVB) Announces Quarterly Earnings Results

Revelation Biosciences (NASDAQ:REVB) announced its earnings results on Thursday. The company reported $15.09 EPS for the quarter, topping the consensus estimate of ($3.66) by $18.75, reports.

Revelation Biosciences Price Performance

Shares of Revelation Biosciences stock traded down $0.08 during trading on Thursday, reaching $1.33. 122,781 shares of the company traded hands, compared to its average volume of 293,737. The firm has a market capitalization of $9.18 million, a PE ratio of -0.01 and a beta of -0.11. Revelation Biosciences has a 1-year low of $1.29 and a 1-year high of $46.31. The company has a 50 day moving average price of $2.58 and a 200-day moving average price of $4.98.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e)” rating on shares of Revelation Biosciences in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Revelation Biosciences presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Revelation Biosciences

A hedge fund recently raised its stake in Revelation Biosciences stock. Armistice Capital LLC lifted its stake in shares of Revelation Biosciences, Inc. (NASDAQ:REVB) by 442.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 434,272 shares of the company’s stock after purchasing an additional 354,272 shares during the quarter. Armistice Capital LLC owned about 6.29% of Revelation Biosciences worth $347,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 12.80% of the company’s stock.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.